Copy this here
Regarding FimaNAC collaboration with top 10 large pharma,
it seems that PCI Biotech was part of the MEDITRANS project sponsored by EU that took place in the Netherlands between 2007-2011 (EUR 14 839 172 total cost) this project is called Targeted delivery of nanomedicine.
https://cordis.europa.eu/project/rcn/81544_en.html
The interesting thing is that both Merk and Bayer were involved in this project (look at participant list in the link above). and you can read the short final report summary in this link below:
https://cordis.europa.eu/result/rcn/52960_en.html
Quote:
"The objectives of the MEDITRANS project have been:
- to demonstrate the potential of emerging materials (carbon-based nanoparticles) for use as carrier materials in targeted nanomedicines;
- to develop highly effective nanomedicines based on candidate materials (already used in proof-of-concept drug delivery studies in animals) by virtue of improved targeting and drug release properties;
- to promote the entry of nanomedicines based on established materials into industrial exploitation activities and clinical proof-of-concept studies;
- to develop high-sensitivity imaging probes properly designed for guiding drug delivery processes in vivo;
- to formulate proprietary industrial drug molecules, already established drugs, and DNA- or RNA-based drugs into targeted nanomedicines with well-characterised and optimised physicochemical properties;
- to optimise the targeting efficiency of the nanomedicines under development by in vitro target recognition studies;
- to improve the intracellular targeting of siRNA / pDNA-loaded nanomedicines in cancer and endothelial cells;
- to maximise the drug availability at the target site by means of external physical stimuli that induce drug release from the targeted nanoparticles ‘on demand’;
- to develop targeted nanomedicines from which release of drug/imaging probe is promoted by physiochemical characteristics of the pathological microenvironment;
- to develop imaging procedures for the monitoring of the various steps in the targeted drug delivery process (nanoparticle targeting and accumulation, drug release, local level of drug and of biomarkers in response to therapy) by means of ‘smart’ imaging probes;
- to optimise biodistribution, targeting efficiency, and therapeutic activity of the nanomedicines under development in suitable animal models of rheumatoid arthritis, Crohn’s disease, multiple sclerosis and cancer;
- to assess the toxicological aspects of selected MEDITRANS nanomedicines;
- to enter selected prototype nanomedicines into an industrial exploitation phase to evaluate their potential to be developed into a marketable product;
- to provide training courses, and access to the Galenos-network, provided for consortium scientists, Small and medium-sized enterprises (SMEs), and key stakeholders;
- to provide effective and efficient dissemination, and demonstration, of the project’s results across Europe."
Also see MEDITRANS- Results in Brief from the EU page
https://cordis.europa.eu/result/rcn/89755_en.html
Pci biotech was part of work package 5 (WP5) and 9(WP9)and below you ll find the full final report for the project where there are many references to pci biotech
2011-12-08 26668 1231694 P4 PUBLISHABLE FINAL ACTIVITY REPORT.pdf (7,5 MB)
for example
page 21
“Brief description of methodologies and approaches employed
The main techniques used are flow cytometry (cellular uptake, determination of endocytic pathways, determination of biological activity), Fluorescence Correlation Spectroscopy (siRNA loading in nanogels, nanogel stability in blood, pDNA stability and pDNA complexation), Single Particle Tracking(dual-color colocalization studies for the endocytic ‘fingerprinting’, following pDNA complexation and dissociation of pDNA from the carrier, following pDNA degradation in buffer and following pDNA protection when complexed to certain gene delivery vehicles).
Photochemical internalisation (PCI) is used to elucidate the effect of an enhanced endosomal escape on the biological activity of nanogels or to enhance the contrast of magnetic resonance imaging”
Now, why am I bringing this up?
Both Merk and Bayer are top 10 large pharma and they both have interacted with pci biotech from 2007 to 2011 through out the MEDITRANS project where FimaNAC was used for the active targeting approach.
I believe they both have deep knowledge of the technology and one of them is likely to be our top 10 pharma partner in the collaboration agreement. although that if you read in the final report that Merck dropped out from the project due to challenges with organisational restructuring/aquiring a company bla bla
I havent digged into a company before like I did for pci biotech, every day I learn something new and I haven’t been any closer to the top 10 pharma name like I feel today. So I am dropping my AstraZeneca theory for now and probably go for Bayer or Merk (to a less extent 
).
